I am an Associate Professor in the Department of Health Policy and Management at Columbia University and a Research Associate at the National Bureau of Economic Research. I received my B.A., M.A., M.Phil. and Ph.D. (all in economics) from Columbia. Most of my research focuses on issues at the intersection of health policy and innovation policy. My current work includes (1) various empirical studies of drug and life science patent policy in the U.S. and developing countries (2) evaluating the validity of different approaches to measure science, innovation and science-technology linkages (3) examining whether and when science is self-correcting (4) assessing the impact of federal indirect cost recovery policy on the biomedical research enterprise. My previous work includes research on the political economy of the the NIH, patent examination and patent quality, and the roles of academic patenting in university-industry technology transfer.
PhD, 2001, Columbia University
M Phil, 2000, Columbia University
MA, 1998, Columbia University
BA, 1996, Columbia University
Honors & Awards
Areas of Expertise
Big Data, Pharmaceutical Statistics, Predictive Modeling/Machine Learning, Research Design and Methods, Statistics and the Law, Global Health, Health Law, Healthcare Economics, Healthcare Policy, Pharmaceudical Industry
Select Global Activities
TRIPS and Pharmaceutical Patenting in Developing Countriess: Prior to the World Trade Organization's Trade-Related Intellectual Property Rights (TRIPS) Agreement, few developing countries granted pharmaceutical patents. TRIPS requires all countries to do so. While pharmaceutical patenting is now universal, countries nonetheless adopt different sorts of pharmaceutical patent systems, setting different standards of patentability. This project, with Ken Shadlen from the London School of Economics, examines the causes of cross-country variation in TRIPS implementation, and consequences for innovation, competition, and access to medicines.
Li, Danielle, Pierre Azoulay, and Bhaven N. Sampat. "The applied value of public investments in biomedical research." Science 356.6333 (2017): 78-81.
Hegde, Deepak, and Bhaven Sampat. "Can private money buy public science? Disease group lobbying and federal funding for biomedical research." Management Science 61.10 (2015): 2281-2298.
Sampat, Bhaven N., and Kenneth C. Shadlen. "Secondary pharmaceutical patenting: A global perspective." Research Policy 46.3 (2017): 693-707.
Hemphill, C. Scott, and Bhaven Sampat. "Drug patents at the Supreme Court." Science 339.6126 (2013): 1386-1387.
Sampat, Bhaven N. "When do applicants search for prior art?." The Journal of Law and Economics 53.2 (2010): 399-416.
Hemphill, C. Scott, and Bhaven N. Sampat. "Evergreening, patent challenges, and effective market life in pharmaceuticals." Journal of health economics 31.2 (2012): 327-339.
Lemley, Mark A., and Bhaven Sampat. "Examiner characteristics and patent office outcomes." Review of Economics and Statistics 94.3 (2012): 817-827.
Azoulay, Pierre, et al. Public R&D investments and private-sector patenting: evidence from NIH funding rules. No. w20889. National Bureau of Economic Research, 2015.
Sampat, Bhaven N., and Frank R. Lichtenberg. "What are the respective roles of the public and private sectors in pharmaceutical innovation?." Health Affairs 30.2 (2011): 332-339.
Sampat, Bhaven, and Heidi L. Williams. How do patents affect follow-on innovation? Evidence from the human genome. No. w21666. National Bureau of Economic Research, 2015.